The Quantellect read.As of Nov 19, 2026, 3 active firms cover Clover Health Investments Corp: 1 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets range widely, $2.50 to $5.50 (about 2.2x), a sign of real disagreement on valuation. The average target of $4.33 sits 4% above the current $4.17. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.08 next quarter toward $0.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Neutral
Strong Buy00%
Buy133%
Neutral267%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$4.33
+4.0% upside
Average target across 3 active firms as of Nov 19, 2026 vs $4.17 current
Highest Target$5.50
Average Target$4.33
Lowest Target$2.50
Detailed analyst forecasts for CLOV
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 1 of 3 active firms rate CLOV a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CLOV EPS & revenue forecast
EPS · NEXT QUARTER
$0.08
Range $0.08 – $0.08 · 1 analysts · +7% YoY
Next period, 1 analysts expect Clover Health Investments Corp to earn $0.08 a share (range $0.08 – $0.08), versus $0.07 a year earlier. Full-year consensus is $0.14, growing to $0.18 the year after.
REVENUE · NEXT QUARTER
$928.6M
Range $906.1M – $960.6M · 1 analysts · +24% YoY
Revenue is expected to reach $928.6M (range $906.1M – $960.6M), +24.0% year-over-year. Full-year consensus is $3.0B, rising to $3.7B next year.
Top analysts covering Clover Health Investments Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLOV.
#1
Richard Close
Canaccord Genuity · Rank #249
Buy
$5.50+32.1% to target
Overall win rate
37%
+ Follow
#2
JY
Jonathan Yong
UBS
Neutral
$5.00+20.0% to target
Coverage
—
+ Follow
#3
Whit Mayo
Leerink Partners
Neutral
$2.50-40.0% to target
Coverage
—
+ Follow
#4
MH
Matt Hewitt
Craig-Hallum
Buy
No targeton CLOV
Coverage
—
+ Follow
CLOV stock forecast FAQ
What is CLOV's average 12-month price target?+
The 3 active firms with a live target average $4.33 for Clover Health Investments Corp over the next 12 months, ranging from a $5.50 high to a $2.50 low, as of Nov 19, 2026.
Is CLOV stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 3 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CLOV?+
The Street-high target is $5.50 (Canaccord Genuity), and the Street-low is $2.50 (Leerink Partners). The average of all 3 active-firm targets is $4.33.
How many active Wall Street firms cover CLOV?+
3 active firms have a recognized rating on Clover Health Investments Corp as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CLOV?+
Among analysts who currently cover CLOV, Richard Close of Canaccord Genuity has the strongest overall Quantellect track record (Rank #249). Their current call is Buy with a $5.50 target.
What is Clover Health Investments Corp's projected EPS for next quarter?+
The consensus estimate is $0.08 per share (range $0.08 – $0.08) across 1 analysts. Full-year EPS is projected at $0.14, rising to $0.18 the following year.
How much revenue is Clover Health Investments Corp expected to report next quarter?+
Consensus revenue is $928.6M (range $906.1M – $960.6M). Full-year revenue is projected at $3.0B, growing to $3.7B next year.
Have analysts been upgrading or downgrading CLOV lately?+
As of Nov 19, 2026, 1 of 3 active firms rate CLOV a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLOV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.